Near Full-Length Genomic Characterization of a Novel HIV-1 B/C Recombinant Form Identified in Guangdong Province, China.
PMID: 33287631
2021
AIDS research and human retroviruses
Abstract: In addition, this B/C recombinant strain contained the non-nucleoside reverse transcriptase inhibitor resistance mutation K103N and the integrase strand transfer inhibitor other resistance mutation L74I according to the Stanford University HIV Drug Resistance Database program.
Increase in HIV-1-transmitted drug resistance among ART-naive youths at the China-Myanmar border during 2009 ~ 2017.
Abstract: HLA genotypes A*02:01/05/14, B*44:15, and C*04:07 predicted the presence of L74I, a mutation recently observed in association with long-acting INSTI cabotegravir virologic failure.
Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Discussion: In Morocco, 5.2% of the study sample contained secondary mutations (L74IM, T97A), while no primary INSTIs-resistance mutations were detected among 77 ART-naive patients.
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
PMID: 33693680
2021
The Journal of antimicrobial chemotherapy
Abstract: The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively.
Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.
PMID: 33800269
2021
International journal of environmental research and public health
Result: This sequence did not harbor any major or accessory drug resistance mutations to INSTIs; however, it presented a polymorphic accessory mutation (L74I) common among 20% of the studied patients but with no significant effect by itself.
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Result: Eleven NOPs (I72V, L74MVI, L101I, T112V, T124A, T124A, G134N, I135V, K136K/Q, V201I and T206S) are part of the CCD, and the remaining five (T218I, L234I, A265V, R269K and S283G) belong to the CTD.
Result: In addition, the remaining other six substitutions; M50I, L74I, L74M, Q95K
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Discussion: The other was on DTG/ABC/3TC and had baseline M184V/I, L74I, M41L and T215Y, the combination of which severely reduces susceptibility to 3TC and ABC.
HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.
PMID: 34714124
2021
AIDS research and human retroviruses
Abstract: No major INSTI resistance mutations were detected; however, the L74I polymorphism was detected in three sequences of the 44 (6.8%).
Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.
Result: The most prevalent RT RAMs among children and adolescents and their relative proportions were as follows: M184V (76.6%, n = 49/64), K103N (45.3%, n = 29/64), Y181C/V/I (28.1%, n = 18/64), T215F/Y (25.0%, n = 16/64), V108I (18.8%, n = 12/64), A98G (15.6%, n = 10/64), G190A (12.5%, n = 8), K101E/H (12.5%, n = 8), M41L (10.9%, n = 7/64), L74I/V (10.9%, n = 7/64), and H221Y (10.9%, n = 7/64) (Figure 1a,b).
HIV mutation literature information.
PMID: 
2021
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT